Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: J Pediatr Hematol Oncol. 2016 Mar;38(2):131–138. doi: 10.1097/MPH.0000000000000506

Table III. FGFR4 polymorphism and MYCN amplification status or Risk group.

Genotype OR (95% CI) P value
MYCN amplified MYCN non-amplified Unknown
GG 13 (37%) 21 (31%) 11 (46%) 1.0
AG 18 (51%) 42 (63%) 9 (38%) 0.5 (0.3-1.2) 0.1
AA 4 (12%) 4 (6%) 4 (16%) 1.8 (0.5-6.7) 0.4
High Risk Non-High Risk Unknown
GG 24 (39%) 16 (31%) 5 (38%) 1.0
AG 33 (54%) 30 (58%) 6 (46%) 0.7 (0.3-1.5) 0.4
AA 4 (7%) 6 (11%) 2 (15%) 0.6 (0.2-2.0) 0.4